Search

Your search keyword '"Harding, James J"' showing total 16 results
Start Over Author "Harding, James J" Publisher wiley
16 results on '"Harding, James J"'

1. Hepatic disease control in patients with intrahepatic cholangiocarcinoma correlates with overall survival

Author

Soares, Kevin C., primary, Jolissaint, Joshua S., additional, McIntyre, Sarah M., additional, Seier, Kenneth P., additional, Gönen, Mithat, additional, Sigel, Carlie, additional, Nasar, Naaz, additional, Cercek, Andrea, additional, Harding, James J., additional, Kemeny, Nancy E., additional, Connell, Louise C., additional, Koerkamp, Bas Groot, additional, Balachandran, Vinod P., additional, D'Angelica, Michael I., additional, Drebin, Jeffrey A., additional, Kingham, T. Peter, additional, Wei, Alice C., additional, and Jarnagin, William R., additional

Published
2023
Full Text
View/download PDF

3. Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single‐arm, phase 2 study

Author

Harding, James J., primary, Yang, Tsai‐Sheng, additional, Chen, Yen‐Yang, additional, Feng, Yin‐Hsun, additional, Yen, Chia‐Jui, additional, Ho, Ching‐Liang, additional, Huang, Wen‐Tsung, additional, El Dika, Imane, additional, Akce, Mehmet, additional, Tan, Benjamin, additional, Cohen, Stacey A., additional, Meyer, Timothy, additional, Sarker, Debashis, additional, Lee, Dae‐Won, additional, Ryoo, Baek‐Yeol, additional, Lim, Ho Yeong, additional, Johnston, Amanda, additional, Bomalaski, John S., additional, O’Reilly, Eileen M., additional, Qin, Shukui, additional, and Abou‐Alfa, Ghassan K., additional

Published
2021
Full Text
View/download PDF

4. Pancreas cancer and BRCA : A critical subset of patients with improving therapeutic outcomes

Author

Momtaz, Parisa, primary, O’Connor, Catherine A., additional, Chou, Joanne F., additional, Capanu, Marinela, additional, Park, Wungki, additional, Bandlamudi, Chaitanya, additional, Berger, Michael F., additional, Kelsen, David P., additional, Suehnholz, Sarah P., additional, Chakravarty, Debyani, additional, Yu, Kenneth H., additional, Varghese, Anna M., additional, Zervoudakis, Alice, additional, Li, Jia, additional, Ku, Geoffrey Y., additional, Park, Jennifer S., additional, Shcherba, Marina, additional, Harding, James J., additional, Goldberg, Zoe, additional, Abou‐Alfa, Ghassan K., additional, Salo‐Mullen, Erin E., additional, Stadler, Zsofia K., additional, Iacobuzio‐Donahue, Christine A., additional, and O’Reilly, Eileen M., additional

Published
2021
Full Text
View/download PDF

6. Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib

Author

El Dika, Imane, primary, Capanu, Marinela, additional, Chou, Joanne F., additional, Harding, James J., additional, Ly, Michele, additional, Hrabovsky, Anna D., additional, Do, Richard K.G., additional, Shia, Jinru, additional, Millang, Brittanie, additional, Ma, Jennifer, additional, O’Reilly, Eileen M., additional, and Abou‐Alfa, Ghassan K., additional

Published
2020
Full Text
View/download PDF

7. Clinical implications of drug‐induced liver injury in early‐phase oncology clinical trials

Author

Mondaca, Sebastian P., primary, Liu, Dazhi, additional, Flynn, Jessica R., additional, Badson, Sandy, additional, Hamaway, Stefan, additional, Gounder, Mrinal M., additional, Khalil, Danny N., additional, Drilon, Alexander E., additional, Li, Bob T., additional, Jhaveri, Komal L., additional, Schram, Alison M., additional, Kargus, Katherine E., additional, Kasler, Mary Kate, additional, Blauvelt, Natalie M., additional, Segal, Neil H., additional, Capanu, Marinela, additional, Callahan, Margaret K., additional, Hyman, David M., additional, Gambarin‐Gelwan, Maya, additional, and Harding, James J., additional

Published
2020
Full Text
View/download PDF

8. Second‐line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes

Author

Lowery, Maeve A., primary, Goff, Laura W., additional, Keenan, Bridget P., additional, Jordan, Emmet, additional, Wang, Rui, additional, Bocobo, Andrea G., additional, Chou, Joanne F., additional, O’Reilly, Eileen M., additional, Harding, James J., additional, Kemeny, Nancy, additional, Capanu, Marianela, additional, Griffin, Ann C., additional, McGuire, Joseph, additional, Venook, Alan P., additional, Abou‐Alfa, Ghassan K., additional, and Kelley, Robin K., additional

Published
2019
Full Text
View/download PDF

9. Regional differences in gallbladder cancer pathogenesis: Insights from a multi‐institutional comparison of tumor mutations

Author

Narayan, Raja R., primary, Creasy, John M., additional, Goldman, Debra A., additional, Gönen, Mithat, additional, Kandoth, Cyriac, additional, Kundra, Ritika, additional, Solit, David B., additional, Askan, Gokce, additional, Klimstra, David S., additional, Basturk, Olca, additional, Allen, Peter J., additional, Balachandran, Vinod P., additional, D’Angelica, Michael I., additional, DeMatteo, Ronald P., additional, Drebin, Jeffrey A., additional, Kingham, T. Peter, additional, Simpson, Amber L., additional, Abou‐Alfa, Ghassan K., additional, Harding, James J., additional, O’Reilly, Eileen M., additional, Butte, Jean M., additional, Matsuyama, Ryusei, additional, Endo, Itaru, additional, and Jarnagin, William R., additional

Published
2018
Full Text
View/download PDF

10. A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma

Author

Lowery, Maeve A., primary, Yu, Kenneth H., additional, Kelsen, David Paul, additional, Harding, James J., additional, Bomalaski, John S., additional, Glassman, Danielle C., additional, Covington, Christina M., additional, Brenner, Robin, additional, Hollywood, Ellen, additional, Barba, Adalberto, additional, Johnston, Amanda, additional, Liu, Kay Chia-Wei, additional, Feng, Xiaoxing, additional, Capanu, Marinela, additional, Abou-Alfa, Ghassan K., additional, and O'Reilly, Eileen M., additional

Published
2017
Full Text
View/download PDF

13. Clinical activity of ipilimumab for metastatic uveal melanoma

Author

Luke, Jason J., primary, Callahan, Margaret K., additional, Postow, Michael A., additional, Romano, Emanuela, additional, Ramaiya, Nikhil, additional, Bluth, Mark, additional, Giobbie‐Hurder, Anita, additional, Lawrence, Donald P., additional, Ibrahim, Nageatte, additional, Ott, Patrick A., additional, Flaherty, Keith T., additional, Sullivan, Ryan J., additional, Harding, James J., additional, D'Angelo, Sandra, additional, Dickson, Mark, additional, Schwartz, Gary K., additional, Chapman, Paul B., additional, Wolchok, Jedd D., additional, Hodi, F. Stephen, additional, and Carvajal, Richard D., additional

Published
2013
Full Text
View/download PDF

15. Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations.

Author

Narayan RR, Creasy JM, Goldman DA, Gönen M, Kandoth C, Kundra R, Solit DB, Askan G, Klimstra DS, Basturk O, Allen PJ, Balachandran VP, D'Angelica MI, DeMatteo RP, Drebin JA, Kingham TP, Simpson AL, Abou-Alfa GK, Harding JJ, O'Reilly EM, Butte JM, Matsuyama R, Endo I, and Jarnagin WR

Subjects
Adenocarcinoma genetics, Adenocarcinoma surgery, Adult, Aged, Aged, 80 and over, Carcinoma, Adenosquamous genetics, Carcinoma, Adenosquamous surgery, Chile, Demography, Female, Follow-Up Studies, Gallbladder Neoplasms genetics, Gallbladder Neoplasms surgery, Humans, Japan, Male, Middle Aged, Prognosis, Survival Rate, United States, Adenocarcinoma pathology, Biomarkers, Tumor genetics, Carcinoma, Adenosquamous pathology, Gallbladder Neoplasms pathology, Mutation
Abstract

Background: Although rare in the United States, gallbladder cancer (GBCA) is a common cause of cancer death in some parts of the world. To investigate regional differences in pathogenesis and outcomes for GBCA, tumor mutations were analyzed from a sampling of specimens., Methods: Primary tumors from patients with GBCA who were treated in Chile, Japan, and the United States between 1999 and 2016 underwent targeted sequencing of known cancer-associated genes. Fisher exact and Kruskal-Wallis tests assessed differences in clinicopathologic and genetic factors. Kaplan-Meier methods evaluated differences in overall survival from the time of surgery between mutations., Results: A total of 81 patients were included. Japanese patients (11 patients) were older (median age, 72 years [range, 54-81 years]) compared with patients from Chile (21 patients; median age, 59 years [range, 32-73 years]) and the United States (49 patients; median age, 66 years [range, 46-87 years]) (P = .002) and had more well-differentiated tumors (46% vs 0% for Chile/United States; P < .001) and fewer gallstone-associated cancers (36% vs 67% for Chile and 69% for the United States; P = .13). Japanese patients had a median mutation burden of 6 (range, 1-23) compared with Chile (median mutation burden, 7 [range, 3-20]) and the United States (median mutation burden, 4 [range, 0-27]) (P = .006). Tumors from Japanese patients lacked AT-rich interaction domain 1A (ARID1A) and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations, whereas Chilean tumors lacked Erb-B2 receptor tyrosine kinase 3 (ERBB3) and AT-rich interaction domain 2 (ARID2) mutations. SMAD family member 4 (SMAD4) was found to be mutated similarly across centers (38% in Chile, 36% in Japan, and 27% in the United States; P = .68) and was univariately associated with worse overall survival (median, 10 months vs 25 months; P = .039). At least one potentially actionable gene was found to be altered in 80% of tumors., Conclusions: Differences in clinicopathologic variables suggest the possibility of distinct GBCA pathogenesis in Japanese patients, which may be supported by differences in mutation pattern. Among all centers, SMAD4 mutations were detected in approximately one-third of patients and may represent a converging factor associated with worse survival. The majority of patients carried mutations in actionable gene targets, which may inform the design of future trials., (© 2018 American Cancer Society.)

Published
2019
Full Text
View/download PDF

16. Immunotherapy in hepatocellular carcinoma: Primed to make a difference?

Author

Harding JJ, El Dika I, and Abou-Alfa GK

Subjects
Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Antineoplastic Agents immunology, B7-H1 Antigen antagonists & inhibitors, CTLA-4 Antigen antagonists & inhibitors, Cancer Vaccines therapeutic use, Clinical Trials as Topic, Cytokines therapeutic use, Hepatitis, Chronic immunology, Humans, Interferons therapeutic use, Nivolumab, Oncolytic Virotherapy methods, Programmed Cell Death 1 Receptor antagonists & inhibitors, Pyrazoles therapeutic use, Quinolines therapeutic use, T-Lymphocytes immunology, Tumor Escape, Antineoplastic Agents therapeutic use, Carcinoma, Hepatocellular immunology, Carcinoma, Hepatocellular therapy, Immunotherapy methods, Liver Neoplasms immunology, Liver Neoplasms therapy
Abstract

Advanced hepatocellular carcinoma (HCC) carries a dismal prognosis and the current treatment is limited to sorafenib, an agent with modest benefit. Preclinical data have indicated that several immunologic mechanisms are at play to promote HCC development and growth while impairing effective antitumor immune surveillance. Several novel approaches geared toward manipulating the immune response to HCC have suggested a therapeutic benefit in early-stage clinical trials, indicating a real potential to augment tumor-specific immunity and improve outcomes in patients with this disease. In the current study, the authors reviewed the barriers to an effective immune response against HCC and contemporary clinical investigations that may be "primed" to alter the natural history of HCC., (© 2015 American Cancer Society.)

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results